Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 21:12:e18486.
doi: 10.7717/peerj.18486. eCollection 2024.

The diagnostic utility of glycosaminoglycans (GAGs) in the early detection of cancer: a systematic review

Sarah Douglah  1 , Reem Khalil  1 , Reem Kanaan  1 , Moza Almeqbaali  1 , Nada Abdelmonem  1 , Marc Abdelmessih  1 , Yousr Khairalla  1 , Natheer H Al-Rawi  1
Affiliations

The diagnostic utility of glycosaminoglycans (GAGs) in the early detection of cancer: a systematic review

Sarah Douglah et al. PeerJ. .

Abstract

Background: Glycosaminoglycans (GAGs) are a family of polysaccharides found abundantly in the extracellular matrix (ECM) of tissues. Research has indicated that the dysregulation of ECM, including changes and disruptions in GAGs, contributes to various cancer hallmarks such as metabolic reprogramming, persistent growth signals, immunosuppression, angiogenesis, tumor invasion, and metastasis.

Objective: This systematic review aims to evaluate the diagnostic accuracy of GAGs, including heparan sulfate (HS), chondroitin sulfate (CS), and hyaluronic acid (HA), in early detection of cancer.

Method: Four databases (PubMed, Scopus, EBSCO, and Ovid) were searched for studies in English within the last 15 years, involving at least 50 human participants. Using a two-stage process: identification and screening, 11 articles were selected and critically appraised using Critical Appraisal Skills Programme (CASP) checklists and Newcastle-Ottawa Scale (NOS) appropriate for each study design.

Result: Eleven studies met the inclusion criteria, encompassing various cancers like renal cell carcinoma (RCC), upper GI cancer (UGI), ovarian cancer, prostate cancer, breast cancer, lung cancer, colorectal cancer and oral cancer. Methodological quality was assessed using two established tools, with no studies exhibiting a high risk of bias. Heparan sulfate levels showed diagnostic potential in renal cancer with a maximum accuracy of 98.9%, achieving 94.7% specificity and 100% sensitivity. Chondroitin sulfate disaccharides emerged as a promising diagnostic marker in ovarian cancer and showed potential as diagnostic markers in renal cancer. However, there were no statistically significant differences in urinary chondroitin sulfate levels between patients and controls in prostate cancer. In breast cancer, hyaluronic acid showed moderate accuracy (AUC = 0.792) in distinguishing metastatic from non-metastatic disease, and a composite score incorporating multiple markers, including HA, showed even higher accuracy (AUC = 0.901) in detecting metastatic breast cancer. HA demonstrated moderate diagnostic accuracy for UGI cancers. Serum HA levels were significantly elevated in patients with oral cancer and pleural malignant mesothelioma and associated with tumor progression in patients with lung cancer. Elevated low molecular weight form of hyaluronan (~6 k Da HA) levels were found in colorectal cancer tissues.

Conclusion: GAGs hold potential as early cancer detection biomarkers. Further validation with larger, diverse populations is needed to validate their diagnostic accuracy and clinical utility.

Keywords: Cancer; Chondroitin sulfate; Gycosaminoglycans; Heparan sulfate; Hyaluronic acid.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1. PRISMA model.
See this image and copyright information in PMC

References

    1. Aghcheli K, Parsian H, Qujeq D, Talebi M, Mosapour A, Khalilipour E, Islami F, Semnani S, Malekzadeh R. Serum hyaluronic acid and laminin as potential tumor markers for upper gastrointestinal cancers. European Journal of Internal Medicine. 2012;23(1):58–64. doi: 10.1016/j.ejim.2011.07.018. - DOI - PubMed
    1. Ahlquist DA. Universal cancer screening: revolutionary, rational, and realizable. npj Precision Oncology. 2018;2(1):23. doi: 10.1038/s41698-018-0066-x. - DOI - PMC - PubMed
    1. Biskup K, Stellmach C, Braicu EI, Sehouli J, Blanchard V. Chondroitin sulfate disaccharides, a serum marker for primary serous epithelial ovarian cancer. Diagnostics. 2021;11(7):1143. doi: 10.3390/diagnostics11071143. - DOI - PMC - PubMed
    1. Bratulic S, Limeta A, Dabestani S, Birgisson H, Enblad G, Stålberg K, Hesselager G, Häggman M, Höglund M, Simonson OE, Stålberg P. Noninvasive detection of any-stage cancer using free glycosaminoglycans. Proceedings of the National Academy of Sciences of the United States of America. 2022;119(50):e2115328119. doi: 10.1073/pnas.2115328119. - DOI - PMC - PubMed
    1. Cheung KL, Graves CRL, Robertson JFR. Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treatment Reviews. 2000;26(2):91–102. doi: 10.1053/ctrv.1999.0151. - DOI - PubMed

Publication types

LinkOut - more resources